Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Swedish Orphan Biovitrum AB (SOBIV)

Stockholm
Currency in SEK
Disclaimer
271.20
-1.00(-0.37%)
Real-time Data
Fair Value
Unlock Value
Day's Range
270.80274.00
52 wk Range
197.90302.00
Bid/Ask
271.00 / 271.40
Prev. Close
272.2
Open
274
Day's Range
270.8-274
52 wk Range
197.9-302
Volume
14,728
Average Volume (3m)
541,228
1-Year Change
12.95%
Shares Outstanding
339,757,114
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
317.70
Upside +17.15%

People Also Watch

425.5
ALFA
+0.28%
41.17
VOLCARb
+0.37%
253.6
AAK
+0.88%
87.64
TEL2b
+0.44%
221.0
SKFb
0.00%
How do you feel today about SOBIV?
Vote to see community's results!
or

Swedish Orphan Biovitrum AB Company Profile

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.

Employees
1556
Market
Sweden
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.